Dyne Therapeutics’ (DYN) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report sent to investors on Friday,Benzinga reports. They currently have a $50.00 price objective on the stock.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 17th. JPMorgan Chase & Co. dropped their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.85.

Dyne Therapeutics Trading Up 1.2%

DYN opened at $11.44 on Friday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -3.21 and a beta of 1.19. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $47.45. The business’s fifty day simple moving average is $10.37 and its 200-day simple moving average is $17.98.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This trade represents a 1.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 6,237 shares of company stock worth $77,760 in the last three months. Corporate insiders own 14.14% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of DYN. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $50,000. KBC Group NV raised its position in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. Arizona State Retirement System lifted its stake in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock valued at $183,000 after acquiring an additional 1,481 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Dyne Therapeutics by 22.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock valued at $201,000 after acquiring an additional 3,496 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its stake in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after acquiring an additional 721 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.